Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2008

Open Access 01-12-2008 | Research

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160

Authors: Yi Lu, Hang-Ping Yao, Ming-Hai Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2008

Login to get access

Abstract

The RON receptor tyrosine kinase regulates epithelial cell homeostasis and tumorigenesis by transducing multiple signals through its functional domains. The present study was to determine the significance of the entire C-terminus in RON or its variant RON160-mediated activities related to cell motility and tumorigenesis. Analysis of protein phosphorylation revealed that elimination of the entire C-terminus significantly impairs the ligand-dependent or independent RON or RON160 phosphorylation and dimerization. Phosphorylation of downstream signaling proteins such as Erk1/2, AKT, and p38 MAP kinase was also diminished in cells expressing the C-terminus-free RON or RON160. These dysfunctional activities were accompanied with the inability of truncated RON or RON160 to mediate cytoplasmic β-catenin accumulation. Functional analysis further demonstrated that truncation of the C-terminus significantly impairs RON or RON160-mediated cell proliferation, morphological changes, and cellular migration. Significantly, oncogenic RON160-mediated tumor growth in athymic nude mice was lost after the deletion of the C-terminus. Thus, the C-terminus is a critical component of the RON receptor. The entire C-terminus is required for RON or RON160-mediated intracellular signaling events leading to various cellular activities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ronsin C, Muscatelli F, Mattei MG, Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993, 8 (5): 1195-1202. Ronsin C, Muscatelli F, Mattei MG, Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993, 8 (5): 1195-1202.
2.
go back to reference Wang MH, Ronsin C, Gesnel MC, Coupeym L, Skeel A, Leonard EJ, Breathnach R: Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 1994, 266 (5182): 117-119. 10.1126/science.7939629.CrossRef Wang MH, Ronsin C, Gesnel MC, Coupeym L, Skeel A, Leonard EJ, Breathnach R: Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 1994, 266 (5182): 117-119. 10.1126/science.7939629.CrossRef
3.
go back to reference Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 1994, 13 (15): 3524-3532. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 1994, 13 (15): 3524-3532.
4.
go back to reference Han S, Stuart LA, Degen SJ: Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry. 1991, 30 (40): 9768-9780. 10.1021/bi00104a029.CrossRef Han S, Stuart LA, Degen SJ: Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry. 1991, 30 (40): 9768-9780. 10.1021/bi00104a029.CrossRef
5.
go back to reference Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM: The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene. 1995, 11 (12): 2627-2637. Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM: The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene. 1995, 11 (12): 2627-2637.
6.
go back to reference Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL, Friezner Degen SJ: The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J Clin Invest. 1999, 103 (9): 1277-12785. 10.1172/JCI6091.CrossRef Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL, Friezner Degen SJ: The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J Clin Invest. 1999, 103 (9): 1277-12785. 10.1172/JCI6091.CrossRef
7.
go back to reference Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chrom Cancer. 2000, 29 (2): 147-156. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N.CrossRef Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chrom Cancer. 2000, 29 (2): 147-156. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N.CrossRef
8.
go back to reference Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI: The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem. 2004, 279 (5): 3726-3732. 10.1074/jbc.M309342200.CrossRef Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI: The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem. 2004, 279 (5): 3726-3732. 10.1074/jbc.M309342200.CrossRef
9.
go back to reference Collesi C, Santoro MM, Gaudino G, Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996, 16 (10): 5518-5526.CrossRef Collesi C, Santoro MM, Gaudino G, Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996, 16 (10): 5518-5526.CrossRef
10.
go back to reference Wang MH, Wang D, Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 2003, 24 (8): 1291-1300. 10.1093/carcin/bgg089.CrossRef Wang MH, Wang D, Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 2003, 24 (8): 1291-1300. 10.1093/carcin/bgg089.CrossRef
11.
go back to reference Wang MH, Kurtz AL, Chen YQ: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis. 2000, 21 (8): 1507-1512. 10.1093/carcin/21.8.1507.CrossRef Wang MH, Kurtz AL, Chen YQ: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis. 2000, 21 (8): 1507-1512. 10.1093/carcin/21.8.1507.CrossRef
12.
go back to reference Wei X, Hao L, Ni S, Liu Q, Xu J, Correll PH: Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity. J Biol Chem. 2005, 280 (48): 40241-40251. 10.1074/jbc.M506806200.CrossRef Wei X, Hao L, Ni S, Liu Q, Xu J, Correll PH: Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity. J Biol Chem. 2005, 280 (48): 40241-40251. 10.1074/jbc.M506806200.CrossRef
13.
go back to reference Wang MH, Lao WF, Wang D, Luo YL, Yao HP: Blocking Tumorigenic Activities of Colorectal Cancer Cells by a Splicing RON Receptor Variant Defective in the Tyrosine Kinase Domain. Cancer Biol Ther. 2007, 6 (7): 1121-1129.CrossRef Wang MH, Lao WF, Wang D, Luo YL, Yao HP: Blocking Tumorigenic Activities of Colorectal Cancer Cells by a Splicing RON Receptor Variant Defective in the Tyrosine Kinase Domain. Cancer Biol Ther. 2007, 6 (7): 1121-1129.CrossRef
14.
go back to reference Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994, 77 (2): 261-271. 10.1016/0092-8674(94)90318-2.CrossRef Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994, 77 (2): 261-271. 10.1016/0092-8674(94)90318-2.CrossRef
15.
go back to reference Yokoyama N, Ischenko I, Hayman MJ, Miller WT: The C terminus of RON tyrosine kinase plays an autoinhibitory role. J Biol Chem. 2005, 280 (10): 8893-8900. 10.1074/jbc.M412623200.CrossRef Yokoyama N, Ischenko I, Hayman MJ, Miller WT: The C terminus of RON tyrosine kinase plays an autoinhibitory role. J Biol Chem. 2005, 280 (10): 8893-8900. 10.1074/jbc.M412623200.CrossRef
16.
go back to reference Xiao ZQ, Chen YQ, Wang MH: Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. Biochem Biophys Res Commun. 2000, 267 (2): 669-675. 10.1006/bbrc.1999.2011.CrossRef Xiao ZQ, Chen YQ, Wang MH: Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. Biochem Biophys Res Commun. 2000, 267 (2): 669-675. 10.1006/bbrc.1999.2011.CrossRef
17.
go back to reference O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS: Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006, 66 (18): 9162-9170. 10.1158/0008-5472.CAN-06-0283.CrossRef O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS: Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006, 66 (18): 9162-9170. 10.1158/0008-5472.CAN-06-0283.CrossRef
18.
go back to reference Wang MH, Wei L, Luo YL, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 2007, 213 (4): 402-411. 10.1002/path.2245.CrossRef Wang MH, Wei L, Luo YL, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 2007, 213 (4): 402-411. 10.1002/path.2245.CrossRef
19.
go back to reference Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998, 16 (22): 2927-33. 10.1038/sj.onc.1201812.CrossRef Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998, 16 (22): 2927-33. 10.1038/sj.onc.1201812.CrossRef
20.
go back to reference Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005, 11 (6): 2222-2228. 10.1158/1078-0432.CCR-04-1761.CrossRef Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005, 11 (6): 2222-2228. 10.1158/1078-0432.CCR-04-1761.CrossRef
21.
go back to reference Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC: The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 2008, 51 (8): 1268-1274. 10.1007/s10350-008-9297-1.CrossRef Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC: The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 2008, 51 (8): 1268-1274. 10.1007/s10350-008-9297-1.CrossRef
22.
go back to reference Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 2005, 92 (10): 1906-1914. 10.1038/sj.bjc.6602593.CrossRef Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 2005, 92 (10): 1906-1914. 10.1038/sj.bjc.6602593.CrossRef
23.
go back to reference Zhou YQ, He C, Chen YQ, Wang D, Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene. 2003, 22 (2): 186-197. 10.1038/sj.onc.1206075.CrossRef Zhou YQ, He C, Chen YQ, Wang D, Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene. 2003, 22 (2): 186-197. 10.1038/sj.onc.1206075.CrossRef
24.
go back to reference Lu Y, Yao HP, Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 2007, 257 (2): 157-164. 10.1016/j.canlet.2007.08.007.CrossRef Lu Y, Yao HP, Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 2007, 257 (2): 157-164. 10.1016/j.canlet.2007.08.007.CrossRef
25.
go back to reference Xu XM, Wang D, Shen Q, Chen YQ, Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 2004, 23 (52): 8464-8474. 10.1038/sj.onc.1207907.CrossRef Xu XM, Wang D, Shen Q, Chen YQ, Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 2004, 23 (52): 8464-8474. 10.1038/sj.onc.1207907.CrossRef
26.
go back to reference Xu XM, Zhou YQ, Wang MH: Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem. 2005, 280 (26): 25087-25094. 10.1074/jbc.M414699200.CrossRef Xu XM, Zhou YQ, Wang MH: Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem. 2005, 280 (26): 25087-25094. 10.1074/jbc.M414699200.CrossRef
27.
go back to reference Wang D, Shen Q, Chen YQ, Wang MH: Collaborative activities of macrophage- stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene. 2004, 23 (9): 1668-1680. 10.1038/sj.onc.1207282.CrossRef Wang D, Shen Q, Chen YQ, Wang MH: Collaborative activities of macrophage- stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene. 2004, 23 (9): 1668-1680. 10.1038/sj.onc.1207282.CrossRef
28.
go back to reference Santoro MM, Penengo L, Orecchia S, Cilli M, Gaudino G: The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene. 2000, 19 (45): 5208-5211. 10.1038/sj.onc.1203819.CrossRef Santoro MM, Penengo L, Orecchia S, Cilli M, Gaudino G: The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene. 2000, 19 (45): 5208-5211. 10.1038/sj.onc.1203819.CrossRef
29.
go back to reference Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther. 2006, 5 (9): 1179-1186.CrossRef Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther. 2006, 5 (9): 1179-1186.CrossRef
30.
go back to reference Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH: Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene. 2002, 21 (22): 3562-3570. 10.1038/sj.onc.1205442.CrossRef Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH: Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene. 2002, 21 (22): 3562-3570. 10.1038/sj.onc.1205442.CrossRef
31.
go back to reference Penengo L, Rubin C, Yarden Y, Gaudino G: c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 2003, 22 (24): 3669-3679. 10.1038/sj.onc.1206585.CrossRef Penengo L, Rubin C, Yarden Y, Gaudino G: c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 2003, 22 (24): 3669-3679. 10.1038/sj.onc.1206585.CrossRef
32.
go back to reference Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G: Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene. 1998, 17 (6): 741-749. 10.1038/sj.onc.1201994.CrossRef Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G: Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene. 1998, 17 (6): 741-749. 10.1038/sj.onc.1201994.CrossRef
33.
go back to reference Iwama A, Yamaguchi N, Suda T: STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J. 1996, 15 (21): 5866-5875. Iwama A, Yamaguchi N, Suda T: STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J. 1996, 15 (21): 5866-5875.
Metadata
Title
Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
Authors
Yi Lu
Hang-Ping Yao
Ming-Hai Wang
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2008
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-27-55

Other articles of this Issue 1/2008

Journal of Experimental & Clinical Cancer Research 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine